David E Geller
Affiliation: Alfred I. duPont Hospital for Children
- Respiratory care and cystic fibrosisDavid E Geller
Aerosol Research Laboratory, Cystic Fibrosis Center, Biomedical Research, Nemours Children s Clinic, 496 S Delaney Avenue, Suite 406A, Orlando FL 32801, USA
Respir Care 54:796-800. 2009..The May and June 2009 issues of the Journal reflect how diligently the participants worked to provide up-to-date reviews and lively discussions of these topics...
- Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosisDavid E Geller
Nemours Children s Clinic, Orlando, Florida 3280, USA
Respir Med 105:S24-31. 2011..Clinicians need to explore both technological and psychological strategies that will assist in the successful maintenance of treatment requirements...
- Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosisDavid E Geller
Nemours Children s Clinic, Division of Pulmonology, Orlando, FL 32806, USA
Chest 122:219-26. 2002....
- Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosaDavid E Geller
Nemours Children s Clinic, Orlando, FL 32801, USA
Am J Respir Crit Care Med 183:1510-6. 2011..New treatment options for CF pulmonary infections are needed...
- Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technologyDavid E Geller
Aerosol Research Laboratory and Cystic Fibrosis Center, Nemours Children s Clinic, Orlando, Florida
J Aerosol Med Pulm Drug Deliv 24:175-82. 2011..The availability of more efficient and convenient treatment options may improve treatment compliance, and thereby therapeutic outcomes in CF...
- The I-neb Adaptive Aerosol Delivery System enhances delivery of alpha1-antitrypsin with controlled inhalationDavid E Geller
Nemours Children s Clinic Aerosol Research Lab, Orlando, Florida 32801, USA
J Aerosol Med Pulm Drug Deliv 23:S55-9. 2010..The purposes of this in vitro study were to determine aerosol characteristics, device efficiency, and delivery time of AAT using the I-neb AAD System with TBM and TIM...
- Aerosol antibiotics in cystic fibrosisDavid E Geller
Aerosol Research Laboratory and Cystic Fibrosis Center, Nemours Children s Clinic, 496 S Delaney Avenue, Suite 406A, Orlando, FL 32801, USA
Respir Care 54:658-70. 2009..Light, porous, dry-powder formulations are also in clinical trials to reduce delivery time. These new formulations and delivery systems promise to expand our armamentarium against microbes while reducing the time burden for patients...
- Clinical side effects during aerosol therapy: cutaneous and ocular effectsDavid E Geller
Nemours Children s Clinic, Orlando, Florida, USA
J Aerosol Med 20:S100-8; discussion S109. 2007..We do not know whether exposed children will have increased risks from ICS later in life. Therefore, it is wise to avoid face and eye deposition when possible, and to use the minimally effective dose...
- Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safetyDavid E Geller
Nemours Children s Clinic, Orlando, Florida 32806, USA
Pediatr Pulmonol 42:307-13. 2007..The development of dry powder inhaled antibiotics may represent an important advance in the treatment of chronic lung infections...
- New liquid aerosol generation devices: systems that force pressurized liquids through nozzlesDavid E Geller
Aerosol Research Laboratory and Cystic Fibrosis Center, The Nemours Children s Clinic, Orlando, FL 32806, USA
Respir Care 47:1392-404; discussion 1404-5. 2002..These novel devices face competition from other technologies as well as financial and regulatory hurdles, but they both offer a marked improvement in the efficiency of pulmonary drug delivery...
- Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery systemDavid E Geller
The Nemours Children s Clinic, 83 W Columbia St, Orlando, FL 32806 1101, USA
Chest 123:28-36. 2003..Second, we wanted to ascertain which AeroDose-delivered tobramycin dose is equivalent to the standard 300-mg dose administered with the PARI LC PLUS...
- Bolus inhalation of rhDNase with the AERx system in subjects with cystic fibrosisDavid Geller
The Nemours Children s Clinic, Orlando, Florida 32806, USA
J Aerosol Med 16:175-82. 2003..This study demonstrated that bolus inhalation of rhDNase was feasible, reasonably well-tolerated, and associated with improvement in pulmonary function in this small group of cystic fibrosis subjects...
- Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhalerDavid E Geller
The Nemours Children s Clinic, Orlando, Florida 32806, USA
Respir Care 50:1313-21; discussion 1321-2. 2005..Clinicians should also have a rudimentary understanding of aerosol principles in order to be able to teach appropriate use of aerosol devices to their patients...
- Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjectsDavid E Geller
Nemours Children s Clinic, 496 S Delaney Ave, Suite 406A, Orlando, Florida 32801, USA
Antimicrob Agents Chemother 55:2636-40. 2011..The pharmacokinetics, safety, and tolerability were similar for the two formulations. MP-376 240 mg (100 mg/ml) is being advanced into late-stage clinical development...
- New aerosol delivery devices for cystic fibrosisKenneth C Kesser
Aerosol Research Laboratory, Nemours Children s Clinic, 496 S Delaney Avenue, Suite 406A, Orlando FL 33801, USA
Respir Care 54:754-67; discussion 767-8. 2009..If successful, these systems will reduce the time burden and improve the clinical outcomes for the CF community...
- Influences of cannula size and flow rate on aerosol drug delivery through the Vapotherm humidified high-flow nasal cannula systemSarah A Perry
Department of Anesthesiology and Critical Care Medicine, Nemours Alfred I duPont Hospital for Children, Wilmington, DE, USA
Pediatr Crit Care Med 14:e250-6. 2013..We investigated the in vitro inspired dose and particle size distribution of albuterol delivered by a vibrating mesh nebulizer through the Vapotherm (Stevensville, MD) humidified high-flow nasal cannula system...
- Positive expiratory pressure changes aerosol distribution in patients with cystic fibrosisBeth L Laube
Department of Pediatrics, Johns Hopkins University, Baltimore, Maryland 21287 2533, USA
Respir Care 50:1438-44. 2005..We hypothesized that aerosol distribution in the lungs of patients with cystic fibrosis changes with positive expiratory pressure (PEP)...
- Pulmonary exacerbations in cystic fibrosisHarvey R Rabin
Foothills Medical Center and University of Calgary, Calgary, Alberta, Canada
Pediatr Pulmonol 37:400-6. 2004..The reproducibility of the model over time was confirmed by application to a subsequent set of data. This model has potential for use as an outcome measure in clinical trials, and to assist in treatment decisions for individual patients...